Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR

Lung Cancer. 2020 Oct:148:170-172. doi: 10.1016/j.lungcan.2020.07.002. Epub 2020 Jul 3.

Authors

Xiangyu Zhang¹, Wenjuan Jiang¹, Nong Yang¹, Yongchang Zhang²

Affiliations

¹ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China.
² Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China. Electronic address: zhangyongchang@csu.edu.cn.

PMID: 32660759
DOI: 10.1016/j.lungcan.2020.07.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Adenocarcinoma of Lung* / genetics
Afatinib / therapeutic use
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
Afatinib
EGFR protein, human
ErbB Receptors